Negative effects of semaglutide on bone in obese mice.

A preclinical study reporting that semaglutide was associated with reduced bone mass and strength in obese male mice, beyond what caloric restriction alone produced, with reversal after discontinuation. As a rodent study confined to male mice, it cannot be extrapolated to people, and the authors explicitly call for clinical investigation. It raises a specific, testable question about skeletal effects that complements the more commonly reported lean-mass concerns.